Alexion Pharmaceuticals (ALXN) Shares Sold by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. trimmed its stake in Alexion Pharmaceuticals (NASDAQ:ALXN) by 15.7% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 261,119 shares of the biopharmaceutical company’s stock after selling 48,672 shares during the period. Candriam Luxembourg S.C.A. owned about 0.12% of Alexion Pharmaceuticals worth $29,106,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Delpha Capital Management LLC purchased a new stake in shares of Alexion Pharmaceuticals in the 4th quarter valued at approximately $102,000. CNB Bank purchased a new stake in shares of Alexion Pharmaceuticals in the 4th quarter valued at approximately $150,000. Financial Gravity Companies Inc. raised its stake in shares of Alexion Pharmaceuticals by 152.0% in the 1st quarter. Financial Gravity Companies Inc. now owns 1,845 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 1,113 shares during the period. Lourd Capital LLC purchased a new stake in shares of Alexion Pharmaceuticals in the 4th quarter valued at approximately $221,000. Finally, Dupont Capital Management Corp purchased a new stake in shares of Alexion Pharmaceuticals in the 1st quarter valued at approximately $220,000. 95.67% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ ALXN opened at $121.07 on Monday. The company has a quick ratio of 2.86, a current ratio of 3.35 and a debt-to-equity ratio of 0.33. Alexion Pharmaceuticals has a 52 week low of $96.18 and a 52 week high of $149.34. The company has a market cap of $26.94 billion, a price-to-earnings ratio of 23.46, a PEG ratio of 1.09 and a beta of 1.11.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping the consensus estimate of $1.50 by $0.18. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The company had revenue of $930.90 million during the quarter, compared to analysts’ expectations of $920.50 million. During the same quarter in the previous year, the business posted $1.38 EPS. The firm’s revenue was up 7.0% on a year-over-year basis. research analysts expect that Alexion Pharmaceuticals will post 6.28 EPS for the current fiscal year.

In other Alexion Pharmaceuticals news, SVP Heidi L. Wagner sold 698 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $119.35, for a total transaction of $83,306.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher J. Coughlin purchased 10,000 shares of the stock in a transaction on Monday, April 30th. The shares were purchased at an average price of $120.79 per share, with a total value of $1,207,900.00. Following the acquisition, the director now directly owns 26,333 shares in the company, valued at $3,180,763.07. The disclosure for this purchase can be found here. Insiders own 4.35% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 2nd. Citigroup lifted their price objective on shares of Alexion Pharmaceuticals from $170.00 to $173.00 and gave the company a “buy” rating in a report on Monday, April 30th. Credit Suisse Group set a $149.00 price objective on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, April 27th. Stifel Nicolaus lifted their price objective on shares of Alexion Pharmaceuticals from $151.00 to $155.00 and gave the company a “buy” rating in a report on Friday, April 27th. Finally, Raymond James restated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Monday, April 23rd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and twenty have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $155.50.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply